BFC Planning, Inc.’s Kymera Therapeutics KYMR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.02K Buy
27
+11
+69% +$1.26K ﹤0.01% 2881
2026
Q2
$1.84K Hold
16
– – ﹤0.01% 3010
2026
Q1
$1.33K Hold
16
– – ﹤0.01% 2688
2025
Q4
$1.24K Hold
16
– – ﹤0.01% 2753
2025
Q3
$906 Buy
+16
New +$722 ﹤0.01% 2641

Other funds holding KYMR

BFC Planning, Inc.'s KYMR Position: Q3 2026 in Review

BFC Planning, Inc. increased its Kymera Therapeutics (KYMR) stake by 69% in Q3 2026, buying an estimated $1.26K and bringing the position to 27 shares worth $3.02K. The position accounts for ﹤0.01% of the portfolio, ranked #2881.

BFC Planning, Inc. first reported a position in KYMR in Q3 2025 and has held it in 5 quarters since. 215 funds tracked by Wall St. Rank hold KYMR as of Q3 2026.

  • BFC Planning, Inc. held 27 shares of Kymera Therapeutics worth $3.02K as of Q3 2026.
  • BFC Planning, Inc. bought 11 Kymera Therapeutics shares in Q3 2026, an estimated $1.26K.
  • Kymera Therapeutics made up ﹤0.01% of BFC Planning, Inc.'s portfolio in Q3 2026, its #2881 holding.
  • BFC Planning, Inc. first reported a position in Kymera Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • 215 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2026.

Based on BFC Planning, Inc.'s 13F filing for Q3 2026, filed 13 Nov 2026.